Compositions comprising hydroxy functional alkyl polyureas are disclosed.

Compositions comprising hydroxy functional alkyl polyureas are disclosed.

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): ##STR00001##
and/or a salt thereof, wherein R.sub.1 is OH or OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): ##STR00001##
and/or a salt thereof, wherein R.sub.1 is OH or OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.

Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

An ink composition including at least one curable monomer; at least one gellant; an optional photoinitiator; and an optional colorant; wherein the ink composition has a viscosity of less than 10.sup.6 centipoise at a temperature of from about 20 C. to about 40 C.; and wherein the ink composition has the characteristics of being both ink jettable and pinnable at a temperature of from about 20 C. to about 40 C.

An ink composition including at least one curable monomer; at least one gellant; an optional photoinitiator; and an optional colorant; wherein the ink composition has a viscosity of less than 10.sup.6 centipoise at a temperature of from about 20 C. to about 40 C.; and wherein the ink composition has the characteristics of being both ink jettable and pinnable at a temperature of from about 20 C. to about 40 C.